| Literature DB >> 18485021 |
C Nakashima1, M Tanioka, K Takahashi, Y Miyachi.
Abstract
Infliximab is a tumour necrosis factor (TNF)-alpha blocking drug classified as a biological response modifier. It has been suggested that the risk of malignancies, especially lymphomas, is increased in patients with rheumatoid arthritis (RA) treated with anti-TNF-alpha antibody therapy. We present a case of malignant lymphoma during the treatment of RA with infliximab and methotrexate.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18485021 DOI： 10.1111/j.1365-2230.2007.02683.x
Source DB: PubMed Journal: Clin Exp Dermatol ISSN： 0307-6938 Impact factor: 3.470